Diabetes

A large study links an early A1c under 6.5% to fewer eye and nerve complications, urging pharmacists to intensify control and monitor retinopathy.

Orforglipron beats oral semaglutide in A1C and weight loss in a head-to-head study for type 2 diabetes.

Navitus Health Solutions conducted a survey of 2000 US adults who have been taking glucagon-like peptide-1 therapies for the past 2 years.

Novo Nordisk’s CagriSema drives 23% weight loss in REDEFINE 4 but misses noninferiority compared with tirzepatide, shaping the next wave of obesity drugs.

New data links glucagon-like peptide-1s to fewer aneurysm ruptures and lower death risk, guiding pharmacists on safer stroke prevention.

Pharmacists help explain the complex evidence, address fears around injections and cost, and help patients integrate lifestyle changes alongside pharmacologic therapy for diabetes care.

Using the PRIME program’s framework, researchers explore a digital-health and pharmacy-based lifestyle intervention for improving risk factors among patients with prediabetes.

Amid common patient threats stemming from severe hypoglycemia, researchers explore how proactive pharmacist outreach can translate to safer prescribing regimens for patients with diabetes.

Amid evolving standards of care in the management of diabetes, researchers explore the role of pharmacists in facilitating continuous glucose monitoring education.

GLP-1 therapies lower C-reactive protein and tumor necrosis factor-alpha, signaling cardiovascular protection; pharmacists tackle cost

Real-world data shows empagliflozin cuts mortality in broader type 2 diabetes patients, supporting wider sodium-glucose co-transporter 2 inhibitor use with careful safety monitoring.

Novo Nordisk's CagriSema shows significant improvements in blood glucose control and weight loss for type 2 diabetes patients in recent trial results.

Episode 7 dives into new standards of care from the American Diabetes Association and what updates are most important for pharmacists.

Pharmacogenomics enhances cardiometabolic disease management by personalizing medication based on genetic profiles, empowering pharmacists to optimize patient care.

Inhaled Technosphere insulin revolutionizes diabetes management for children and pregnant women, addressing treatment adherence and psychological barriers effectively.

A plant-based lifestyle intervention can lead to diabetes remission and weight loss, transforming traditional diabetes management strategies.

High-dose vitamin D3 shows promise in improving metabolic health for type 2 diabetes patients, enhancing glycemic control alongside traditional treatments.

GLP-1 therapies gain popularity, but patient adherence struggles due to fragmented support and emotional barriers.

Gestational diabetes significantly impacts postpartum cardiovascular health, especially in women over 35, highlighting the need for timely interventions.

Episode 6 explores what pharmacists in the diabetes space need to know about outcomes data, safety, and when to escalate LDL-lowering therapy.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discussed potential safety concerns and the pharmacist’s role in managing insulin.

During her time at ASHP Midyear 2025, Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, returned to discuss all available insulin pump options.

Oral semaglutide (Rybelsus) reduces the risk of major adverse cardiovascular events in adults with high-risk type 2 diabetes, based on data from the SOUL trial.

In an exploration of key stakeholders’ perspectives, researchers assess a lifestyle intervention for cardiometabolic health among women during or after pregnancy.

Pharmacists play a vital role in integrating diabetes and depression care, enhancing patient outcomes through screening, individualized treatment, and collaborative approaches.